Active substances
C + Meningococcal group a + W135 + Y
- SFDA 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ARAMEN POWDER SOLUTION FOR INJECTION (PFS+VIAL) | Injection · Intramuscular use | 1 Pre-filled syringe | SAR 246.40 | Biological · Prescription | ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO) | Withdrawn by MAH · Not Marketed | |
| ARAMEN POWDER SOLUTION FOR INJECTION (VIAL+VIAL) | powder for solution for injection · Intramuscular use | 1 Vial | SAR 246.40 | Biological · Prescription | ARAB COMPANY FOR PHARMACEUTICAL PRODUCTS (ARABIO) | Withdrawn by MAH · Not Marketed | |
| MENCEVAX ACWY 50MCG\0.5ML VIAL | 100 µ/ml | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 64.40 | Biological · Prescription | PFIZER | Withdrawn by MAH · Not Marketed |
| MENCEVAX ACWY 50MCG\0.5ML VIAL | 100 µ/ml | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 64.40 | Biological · Prescription | GLAXOSMITHKLINE (GSK) | Withdrawn by MAH · Not Marketed |
| MENVEO POWDER SOLUTION FOR INJECTION | Powder and solution for solution for injection · Intramuscular use | 1 Vial | SAR 246.40 | Biological · Prescription | NOVARTIS VACCINE AND DIAGNOSTICS S.R.I | Withdrawn by MAH · Not Marketed | |
| NIMENRIX solution for injection | Powder and solvent for solution for injection · Intramuscular use | 1 Vial | SAR 158.95 | Biological · Prescription | GLAXO SAUDI ARABIA | Withdrawn by MAH · Not Marketed |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.